8-K filing — Lineage Cell Therapeutics, Inc. (LCTX)
Filed: 2026-08-06 AccNo: 0001193125-26-338020 Size: 793 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
Lineage Cell Therapeutics Q2 EPS $(0.03) Misses $(0.02) Estimate, Sales $1.069M Miss $1.531M Estimate
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 6, 2026, 8:02 PM
- Checked
- Aug 6, 2026, 8:02 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Lineage Cell Therapeutics Updates COR1 Corneal Cell Transplant Program; Highlights Scalable Allogeneic Production Via AlloSCOPE Platform And Plans Conference Call Today
Company Will Host Conference Call Today at 4:30 PM ET / 1:30 PM PTCOR1 Aims to Provide an "Off the Shelf" Supply of Allogeneic CEnCs for Patients Suffering from Corneal Endothelial DiseaseUtilizes the Company’s
Read original at benzinga